Contemporary medical management of peripheral artery disease
MP Bonaca, NM Hamburg, MA Creager - Circulation research, 2021 - Am Heart Assoc
Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis. Modifiable
risk factors including cigarette smoking, dyslipidemia, diabetes, poor diet quality, obesity …
risk factors including cigarette smoking, dyslipidemia, diabetes, poor diet quality, obesity …
[HTML][HTML] The role of the coagulation system in peripheral arterial disease: interactions with the Arterial Wall and its vascular microenvironment and implications for …
G Miceli, MG Basso, G Rizzo, C Pintus… - International Journal of …, 2022 - mdpi.com
Peripheral artery disease (PAD) is a clinical manifestation of atherosclerotic disease with a
large-scale impact on the economy and global health. Despite the role played by platelets in …
large-scale impact on the economy and global health. Despite the role played by platelets in …
Rivaroxaban and aspirin in peripheral artery disease lower extremity revascularization: impact of concomitant clopidogrel on efficacy and safety
Background: The VOYAGER PAD trial (Vascular Outcomes Study of ASA Along With
Rivaroxaban in Endovascular or Surgical Limb Revascularization for Peripheral Artery …
Rivaroxaban in Endovascular or Surgical Limb Revascularization for Peripheral Artery …
Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials
M Galli, D Capodanno, S Benenati… - European Heart …, 2022 - academic.oup.com
Aims Low-dose (LD) direct oral anticoagulants (DOACs) in adjunct to antiplatelet therapy,
known as dual-pathway inhibition (DPI), have been tested to prevent ischaemic events in …
known as dual-pathway inhibition (DPI), have been tested to prevent ischaemic events in …
Safety and efficacy of P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary interventions
Introduction: Antiplatelet therapy represents a key strategy for the prevention of thrombotic
complications in patients with both acute and chronic coronary syndromes, particularly those …
complications in patients with both acute and chronic coronary syndromes, particularly those …
Switching from dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor to dual pathway inhibition with aspirin plus vascular-dose rivaroxaban: the Switching Anti …
Background To date, there are no data on switching to dual pathway inhibition (DPI) patients
who have completed a guideline-recommended dual antiplatelet therapy (DAPT) regimen …
who have completed a guideline-recommended dual antiplatelet therapy (DAPT) regimen …
[HTML][HTML] Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits
Background Patients with peripheral artery disease (PAD) requiring lower extremity
revascularization (LER) have a high risk of adverse limb and cardiovascular events. The …
revascularization (LER) have a high risk of adverse limb and cardiovascular events. The …
Antithrombotic Treatment in Coronary Artery Disease
G Siasos, V Tsigkou, E Bletsa… - Current …, 2023 - ingentaconnect.com
Coronary artery disease exhibits growing mortality and morbidity worldwide despite the
advances in pharmacotherapy and coronary intervention. Coronary artery disease is …
advances in pharmacotherapy and coronary intervention. Coronary artery disease is …
Dual pathway inhibition in patients with atherosclerotic disease: pharmacodynamic considerations and clinical implications
Introduction The persistence of elevated rates of ischemic recurrences despite the use of
antiplatelet therapy among patients with atherosclerotic disease together with the …
antiplatelet therapy among patients with atherosclerotic disease together with the …
Pharmacodynamic profiles of dual-pathway inhibition with or without clopidogrel versus dual antiplatelet therapy in patients with atherosclerotic disease
Aim Inhibition of thrombin-mediated signaling processes using a vascular dose of
rivaroxaban in adjunct to antiplatelet therapy, known as dual-pathway inhibition (DPI) …
rivaroxaban in adjunct to antiplatelet therapy, known as dual-pathway inhibition (DPI) …